Merck announced that its PD-1 inhibitor pembrolizumab (trade name: pembrolizumab) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of locally advanced cervical cancer in China. It is used in combination with radiotherapy and chemotherapy for the treatment of stage III-IVA cervical cancer patients in the International Federation of Obstetrics and Gynecology (FIGO) 2014. The approval of this new indication is based on data from the global phase III clinical trial KEYNOTE-A18.